Geneseeq, Illumina to develop and commercialize comprehensive cancer in-vitro diagnostic NGS kit in China

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Geneseeq Technology Inc. and Illumina Inc. are working together to develop comprehensive in-vitro diagnostic NGS testing kits (IVD kits) for cancer, using Illumina’s NextSeq 550 Dx sequencing platform.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login